Aradigm (ARDM) Receiving Somewhat Favorable News Coverage, Study Finds
Media headlines about Aradigm (NASDAQ:ARDM) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aradigm earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.5534139093863 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several research analysts have recently commented on ARDM shares. Zacks Investment Research raised Aradigm from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research note on Tuesday, September 5th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $10.00 price objective (up previously from $7.50) on shares of Aradigm in a research note on Monday, September 25th.
Shares of Aradigm (NASDAQ ARDM) traded down $0.06 on Wednesday, reaching $5.12. The company had a trading volume of 64,200 shares, compared to its average volume of 160,098. Aradigm has a 52 week low of $0.78 and a 52 week high of $5.94. The company has a debt-to-equity ratio of -1.59, a quick ratio of 1.65 and a current ratio of 1.65.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/aradigm-ardm-receiving-somewhat-favorable-news-coverage-study-finds/1774646.html.
Aradigm Company Profile
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with MarketBeat.com's FREE daily email newsletter.